Korea warns of rare vision-loss risk linked to GLP-1 drugs

The Ministry of Food and Drug Safety issued a safety alert Wednesday to medical professionals and patients over a potential risk of a rare eye condition associated with GLP-1 obesity drugs, including popular obesity treatments Wegovy and Mounjaro. The move follows safety measures by overseas regulators concerning nonarteritic anterior ischemic optic neuropathy (NAION), a condition caused by reduced blood flow to the optic nerve that can lead to sudden, potentially permanent vision loss. In June last year, the European Medicines Agency classified it as a very rare side effect of semaglutide, the active ingredient in Wegovy, estimating it may affect up to 1 in 10,000 users. The U.S. Food and Drug Administration asked drugmakers Monday to add a possible increased risk of NAION to the warnings and precautions on GLP-1 drug labels. The letter advises medical professionals to stop treatment and have patients examined immediately if NAION is suspected in those taking GLP-1 drugs, which aid weight loss by mimicking a hormone that regulates appetite and blood sugar. Patients with related symptom